No profile data available.
bioAffinity Technologies, Inc. (BIAF) is a healthcare company in the medical testing laboratories industry, based in San Antonio, United States, with about 57 full-time employees.
It reported revenue of $6.11 million for fiscal year 2025, down 34.8% from fiscal year 2024, and net income of -$14.91 million. Its largest business segment, Laboratory Services, brought in 100% of segment revenue in fiscal year 2025. Its market capitalization was $5.51 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services.
bioAffinity Technologies reported $6.11 million in revenue for fiscal year 2025, down 34.8% from $9.36 million in fiscal year 2024.
Laboratory Services, with $6.16 million or 100% of segment revenue in fiscal year 2025. Next: Diagnostic R&D (under 1%).
$5.51 million as of October 9, 2026.
Listed companies of a similar size in the same industry (medical testing laboratories) include Precipio, Inc. (PRPO), Interpace Biosciences, Inc. (IDXG), Psychemedics Corporation (PMDI), RushNet, Inc. (RSHN).